Delgado C, et al. A unifying approach for GFR estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. JASN [published online September 22, 2021]. doi: 10.1053/j.ajkd.2021.08.003

• PubMed
Delgado C, A unifying approach for GFR estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. JASN [published online September 22, 2021]. doi: 10.1053/j.ajkd.2021.08.003)| false
• Search Google Scholar
• Export Citation

Inker LA, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med 2021; 385:1737–1749. doi: 10.1056/NEJMoa2102953

• PubMed
Inker LA, New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med 2021; 385:1737–1749. doi: 10.1056/NEJMoa2102953)| false
• Search Google Scholar
• Export Citation

Hall VG, et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med 2021; 385:1244–1246. doi: 10.1056/NEJMc2111462

• PubMed
Hall VG, Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med 2021; 385:1244–1246. doi: 10.1056/NEJMc2111462)| false
• Search Google Scholar
• Export Citation

Boyarsky BJ, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA 2021; 325:2204. doi: 10.1001/jama.2021.7489

• PubMed
Boyarsky BJ, Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA 2021; 325:2204. doi: 10.1001/jama.2021.7489)| false
• Search Google Scholar
• Export Citation

Kamar N, et al. Assessment of 4 doses of SARS-CoV-2 messenger RNA-based vaccine in recipients of a solid organ transplant. JAMA Netw Open 2021; 4:e2136030. doi: 10.1001/jamanetworkopen.2021.36030

• PubMed
Kamar N, Assessment of 4 doses of SARS-CoV-2 messenger RNA-based vaccine in recipients of a solid organ transplant. JAMA Netw Open 2021; 4:e2136030. doi: 10.1001/jamanetworkopen.2021.36030)| false
• Search Google Scholar
• Export Citation

Pfizer's novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study. Pfizer, November 5, 2021. Accessed November 16, 2021. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate

• PubMed
Pfizer's novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study. Pfizer, November 5, 2021. Accessed November 16, 2021. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate)| false
• Search Google Scholar
• Export Citation

Merck and Ridgeback's molnupiravir, an oral COVID-19 antiviral medicine, receives first authorization in the world. Business Wire November 4, 2021. Accessed November 19, 2021. https://www.businesswire.com/news/home/20211104005560/en/Merck-and-Ridgeback%E2%80%99s-Molnupiravir-an-Oral-COVID-19-Antiviral-Medicine-Receives-First-Authorization-in-the-World

• PubMed
Merck and Ridgeback's molnupiravir, an oral COVID-19 antiviral medicine, receives first authorization in the world. Business Wire November 4, 2021. Accessed November 19, 2021. https://www.businesswire.com/news/home/20211104005560/en/Merck-and-Ridgeback%E2%80%99s-Molnupiravir-an-Oral-COVID-19-Antiviral-Medicine-Receives-First-Authorization-in-the-World)| false
• Search Google Scholar
• Export Citation

Centers for Medicare & Medicaid Services, Department of Health and Human Services. Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model. Federal Register November 8, 2021; 86:61874. https://www.aapc.com/codes/webroot/upload/general_pages_docs/document/2021-23907.pdf

• PubMed
Centers for Medicare & Medicaid Services, Department of Health and Human Services. Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model. Federal Register November 8, 2021; 86:61874. https://www.aapc.com/codes/webroot/upload/general_pages_docs/document/2021-23907.pdf)| false
• Search Google Scholar
• Export Citation

117th Congress (2021–2022). H.R.5426 - Improving Access to Home Dialysis Act of 2021. Congress.gov, September 29, 2021. https://www.congress.gov/bill/117th-congress/house-bill/5426/text

• PubMed
117th Congress (2021–2022). H.R.5426 - Improving Access to Home Dialysis Act of 2021. Congress.gov, September 29, 2021. https://www.congress.gov/bill/117th-congress/house-bill/5426/text)| false
• Search Google Scholar
• Export Citation